Aurora Cannabis has responded to Curaleaf's unsolicited hostile takeover bid by disputing Curaleaf's claims about Aurora's business performance and growth. Aurora highlights its 17% year-over-year international revenue growth, especially in Germany and the UK, and its strong financial results including record revenues and adjusted EBITDA. The company urges shareholders to take no action until the Board and Special Committee provide a formal recommendation. Aurora emphasizes its valuable EU-GMP manufacturing facilities and ongoing expansion in key medical cannabis markets as reasons to reject Curaleaf's offer, which it views as opportunistic and undervaluing the company.
Tilray Brands' stock rose 6% following the U.S. Treasury's announcement to double buybacks of long-term government debt, which lowered yields and boosted speculative stocks. Despite this gain, Tilray remains down 48% year to date, underperforming its...
Aurora Cannabis has acquired Internode Pharma Limited and HAP Pharma Limited, two licensed UK companies involved in importing, wholesaling, and pharmacy services. This acquisition gives Aurora direct control over the UK supply chain, enabling it to b...
